Synvista Therapeutics, Inc
14
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
35.7%
5 terminated/withdrawn out of 14 trials
64.3%
-22.2% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Effects of Exercise Training and AGE-crosslink Breaker on Cardiovascular Structure and Function
Role: collaborator
The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)
Role: lead
Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)
Role: lead
The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure
Role: lead
The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure
Role: lead
STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH
Role: lead
The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling
Role: lead
Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis
Role: lead
Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)
Role: lead
Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure
Role: lead
Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
Role: lead
A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)
Role: lead
Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease
Role: lead
The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension
Role: lead
All 14 trials loaded